Founders come to me having framed this as a technology question: Zocdoc, Doctolib, or build my own, which is the best platform? That is the wrong question, and it leads to expensive answers. This is not a comparison of three products. It is a decision between two very different things you might want, distribution or ownership, dressed up as a three-way bake-off. Once you see it that way, the answer usually becomes obvious, and it is often not the one the founder walked in expecting.
The Three-Door Decision
I frame every one of these conversations as three doors, not three products. Each door leads somewhere genuinely different, and the right one depends entirely on who you are, a practice wanting patients, or a founder building a business.
Zocdoc and Doctolib: same behaviour, two markets
Start by understanding what the two leaders actually are, because founders often blur them. Zocdoc is the US leader in online doctor booking. It grew up inside American healthcare, so filtering doctors by insurance is central to how it works, and the whole experience is shaped around that reality. Doctolib is the leading European equivalent, strong in France, Germany and neighbouring countries, operating under GDPR and sitting closer to the mix of public and private health systems in those markets. If you want the deeper anatomy of how such a platform earns and operates, our business model breakdown lays it out.
The important insight is that these are not competitors you would pick between as a founder. They are proof, in two different regulatory environments, that patients will book doctors online at scale. That proof is exactly what makes the third door viable. You are not betting on an unproven behaviour, you are choosing where to serve it.
It also matters that the two leaders are shaped by their markets in ways you cannot simply copy across borders. Zocdoc's deep integration with insurance filtering reflects a US reality that barely exists in a single-payer or mixed European system. Doctolib's closeness to European health systems and its GDPR-native posture reflect a regulatory environment a US-first tool would have to retrofit. This is a genuinely important lesson for anyone tempted to "just clone the leader": a platform is only excellent because it is tuned to one market's rules and habits. Lift it into a different market and the very things that made it strong become mismatches. That is another reason building your own for a specific market can beat importing a model that was optimised for somewhere else.
When to walk through a leader's door
Be honest about which person you are. If you are a clinic or a doctor who simply wants more patients, in a market where a leader is already dominant, joining that leader is often the smart, unglamorous answer. You get instant distribution, the compliance burden largely sits with them, and you skip the entire cost and risk of building. Do not build a platform to solve a problem a listing on an existing one solves. I have talked practices out of custom builds precisely because they wanted patients, not a product, and those are two different things.
The tell is what you would do the day after launch. If your answer is "market it, get patients booking, and improve it for years," you are a founder building a business, and ownership matters. If your answer is "list my slots and wait for bookings," you want distribution, and a leader gives you that faster and cheaper than any build. Neither answer is better in the abstract. They are answers to different lives, and picking the wrong one is how a busy clinic ends up maintaining software it never needed, or how a founder ends up renting their business from a platform that can change the rules on them.
Tell us what you have in mind. We turn AI prototypes and fresh ideas into shipped, scalable products, from India, for the US and UK.
When to build your own
The third door is right when three things are true. First, there is a real gap the leaders do not focus on, an underserved specialty, a region, a country with no dominant player. Second, you can access doctor supply in that gap. Third, you want to own the product, the data and the economics rather than rent them. If those line up, building is not just viable, it is the better choice, because you are not fighting a leader on their turf, you are creating a platform where none exists.
What you gain by building is control and margin: your own features, your own fee structure, the patient relationship and the data as yours. What you take on is the compliance responsibility, HIPAA in the US, GDPR and UK-GDPR in Europe and the UK, plus NHS context where relevant. That is real, but it is manageable when the compliance spine is designed in from the start. Our region-by-region build guide for the US, UK and EU walks through exactly that.
The reason this trade is so clarifying is that it cuts through feature envy. A founder staring at Doctolib's polish feels behind before they start. But polish is a control-and-ownership asset they are choosing to build, not a distribution shortcut they are missing. Once you accept that you are picking a corner rather than a feature count, the anxiety drops and the decision gets honest: do you need patients this quarter, or do you want a business you own for the next decade?
What everyone gets wrong: comparing feature lists
The classic mistake is to line up Zocdoc's features, Doctolib's features, and a spec for your own, and try to decide by counting. That comparison is a trap, because it quietly assumes your goal is to replicate a mature platform. It is not, and it should not be. A concrete example of the right thinking: a founder wanted to build "a better Doctolib" for a European country where Doctolib was already strong. That is a feature-list fight they would lose. We reframed it around an underserved specialty in a neighbouring market with no leader, where their doctor relationships actually were, and suddenly the build made sense with a fraction of the features. The lesson is that the winning custom platform is not a smaller clone of a leader, it is a focused product for a gap the leader ignores. Trying to match every feature on day one is how founders overspend and stall, the same over-building instinct I warn against constantly, do not try to outrun everyone from day one.
The honest recommendation
So, Zocdoc versus Doctolib versus build your own? If you are a practice wanting patients in a market a leader owns, join the leader, that is not defeat, it is efficiency. If you are a founder with doctor supply in an underserved niche and you want to own a real business, build, and build lean for that niche rather than broad against an incumbent. The two are answers to different questions, and the expensive errors come from confusing them. This is precisely the decision, and the timing behind it, that we unpack in why launch a doctor booking platform in 2027.
When building is genuinely the right door, we help founders scope it around a winnable niche and ship it lean, from India for US, UK and EU markets, with source code and accounts in your name from day one. And when it is not the right door, we will tell you. I would rather talk you out of a build you do not need than sell you one you will not sustain.
Frequently asked questions
What is the difference between Zocdoc and Doctolib?
Both are online doctor booking marketplaces, but they grew in different markets. Zocdoc is the US leader, built around American healthcare where filtering doctors by insurance is central. Doctolib is the leading European equivalent, strong in France, Germany and nearby countries, operating under GDPR and closer to public and private health systems there. Same core behaviour, different market shape.
Should I join Zocdoc or Doctolib, or build my own?
Join a leader if you are a practice that simply wants more patients in a market they already dominate. Build your own if you are a founder chasing an underserved niche or region the leaders do not focus on, or if you need control the platforms will not give you over features, data and economics. The decision is about whether you want distribution or ownership.
When does building your own actually make sense?
When there is a real gap the leaders do not serve, you can access doctor supply in that gap, and you want to own the product, the data and the economics rather than rent them. A custom build is the wrong choice if you just want more patients in a city a leader already owns, and the right choice if you are creating a platform for a niche nobody has claimed.
Is building my own doctor booking platform expensive?
It is a real investment, but far less than most founders expect if you build lean and offshore. A focused first version covering the core booking loop in one niche is achievable, and building with a senior offshore team costs a fraction of onshore rates. The mistake is trying to match every feature of a mature leader on day one instead of owning one niche well.
Can I compete with Zocdoc or Doctolib head-on?
In their strongest cities and specialties, realistically no, they have years of supply and brand there. In an underserved niche or region, yes. Marketplaces are won locally, so the winning strategy is never to beat a leader everywhere, it is to own one specialty in one place better than anyone, then expand.
What do I give up by joining a platform instead of building?
Control and margin. On someone else's platform you follow their rules, their fee structure, their feature roadmap, and you do not own the patient relationship or the data in the way you would on your own product. You gain instant distribution and lose ownership. Which trade is right depends on whether you are a practice or a founder building a business.
Does compliance differ between these options?
Yes. Join a leader and much of the compliance burden sits with them. Build your own and you own it, HIPAA in the US, GDPR and UK-GDPR in Europe and the UK, plus NHS context where relevant. That is a real responsibility, but it is manageable when the compliance spine is designed in from the start rather than retrofitted.
How does appico help me decide and build?
We help you run the decision honestly first, distribution versus ownership, and if building your own is right, we scope it around a winnable niche and ship it lean, from India for US, UK and EU founders, with source code and accounts in your name. We would rather talk you out of a build you do not need than sell you one you will not sustain.
“Disciplined, committed, over-delivers. Three years in, I would re-hire any day.”
“A factory of ideas.”
“A fantastic-looking and performing website.”
Talk to the team, we reply within 24 hours, and the first consultation is free.
Start a conversation →